InvestorsHub Logo
Followers 0
Posts 1200
Boards Moderated 0
Alias Born 05/05/2017

Re: None

Wednesday, 05/10/2017 12:13:08 PM

Wednesday, May 10, 2017 12:13:08 PM

Post# of 44784
Even a 'conditional' or 'restricted' approval would bring revenue to PSTI quickly. LIKE it did for Amgen with Neupogen, within 6 months of their primate ARS trial. FACT. Amgen/Sanofi began selling nearly 2 years before the FDA indication (Nov 2015)- Why not us? See for yourself

BARDA seeks Amgen's Neupogen, Sanofi's Leukine for nuke attack countermeasures

This article was originally published in Scrip

27 Sep 2013
NEWS

https://scrip.pharmamedtechbi.com/SC022896/BARDA-seeks-Amgens-Neupogen-Sanofis-Leukine-for-nuke-attack-countermeasures

PUT UP OR SHUT UP - THIS IS MAKE OR BREAK - YOU HAVE IT, OR YOU DON'T